Skip to content
Weight Loss Index

GIP/GLP-1 Receptor Agonists

GIP/GLP-1 receptor agonists activate both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. In the current US obesity-treatment database, the class connects tirzepatide to Zepbound, Mounjaro, Eli Lilly, and the SURMOUNT clinical program.

The mechanism and product record reviewed here is current to July 23, 2026. Mechanism, indication, label, trial, and development status should be checked separately because sharing a receptor target does not transfer evidence or approval between products.

Reference record

Section titled “Reference record”
Field GIP/GLP-1 receptor agonist record
Entity type Mechanism and pharmacologic-class record
Receptors GIP receptor and GLP-1 receptor
Approved active ingredient in this US obesity-treatment record Tirzepatide
US obesity product Zepbound
Adjacent US diabetes product Mounjaro
Principal company Eli Lilly
Major obesity-development program SURMOUNT

The current Zepbound label identifies tirzepatide as a GIP receptor and GLP-1 receptor agonist and describes the product-specific clinical-pharmacology record.

What dual-receptor agonism means

Section titled “What dual-receptor agonism means”

The class name describes receptor activity, not the number of active ingredients. Tirzepatide is one active ingredient that selectively binds to and activates both the GIP and GLP-1 receptors. It is not a fixed-dose combination of a separate GIP drug and a separate GLP-1 drug.

Term Meaning in this record What it does not establish
GIP receptor agonism Activity at the receptor targeted by native GIP An approved indication or product identity by itself
GLP-1 receptor agonism Activity at the receptor targeted by native GLP-1 Equivalence with every single-receptor GLP-1 product
GIP/GLP-1 receptor agonist One active ingredient engaging both receptor systems Two active ingredients, automatic superiority, or interchangeability
Dual incretin Common shorthand for the two incretin-related receptor activities A universal regulatory class name or identical label language in every market

The Zepbound label states that GLP-1 physiologically regulates appetite and caloric intake and that nonclinical evidence suggests GIP activity may also contribute to food-intake regulation. It also describes effects on calorie intake, glucose-dependent insulin secretion, glucagon secretion, insulin sensitivity, and gastric emptying. Those product-specific statements should not be generalized to every future molecule assigned to the broader class.

Ingredient and product map

Section titled “Ingredient and product map”
Record Role in the class Regulatory boundary
Tirzepatide Active ingredient engaging GIP and GLP-1 receptors Ingredient identity does not carry one universal indication
Zepbound US tirzepatide product for obesity-related indications Its adult weight-reduction and obstructive-sleep-apnea label is product-specific
Mounjaro US tirzepatide product for type 2 diabetes Its diabetes label is separate from Zepbound
Eli Lilly Originator, clinical sponsor, regulatory applicant, and principal commercial company Company association does not identify every manufacturing or distribution role

FDA first approved a tirzepatide product as Mounjaro on May 13, 2022. FDA approved Zepbound on November 8, 2023, creating a separate product record for long-term weight reduction and maintenance in a defined adult population. On December 20, 2024, FDA added a moderate-to-severe obstructive-sleep-apnea indication for adults with obesity.

The FDA Mounjaro approval snapshot, FDA Zepbound original approval notice, and FDA Zepbound obstructive-sleep-apnea notice support those dated product distinctions.

Position among adjacent incretin strategies

Section titled “Position among adjacent incretin strategies”

Mechanism-level comparison is useful for mapping the industry, but receptor grouping is only one comparison dimension.

Strategy Example connected to the obesity-treatment database Key distinction
GLP-1 receptor agonism Semaglutide in Wegovy; liraglutide in Saxenda; orforglipron in Foundayo GLP-1 receptor activity without GIP receptor agonism as the defining class feature
GIP/GLP-1 receptor agonism Tirzepatide in Zepbound and Mounjaro Dual GIP and GLP-1 receptor activity in one ingredient
GIP/GLP-1/glucagon receptor agonism Investigational retatrutide Adds glucagon receptor activity and remains a development-stage record as of July 23, 2026
GLP-1/amylin strategies Novo Nordisk combination and multi-receptor programs Connect incretin activity to amylin rather than GIP as the adjacent pathway

A current approved-product anchor for the GLP-1 column is the FDA Foundayo label. Retatrutide’s triple-receptor classification and investigational phase 3 status are documented in the TRIUMPH-1 registry record and Lilly’s May 2026 topline announcement.

A broader target set does not, by itself, establish better efficacy, safety, durability, tolerability, access, or commercial performance. Those conclusions require product-specific evidence with aligned populations, doses, comparators, endpoints, durations, and dates.

Clinical-program relationships

Section titled “Clinical-program relationships”

The SURMOUNT program is the main obesity-development program connecting tirzepatide to the GIP/GLP-1 class. Individual trials address different populations and questions:

  • SURMOUNT-1 studied adults without type 2 diabetes who had obesity or overweight with weight-related comorbidities.
  • SURMOUNT-2 studied adults with type 2 diabetes who had obesity or overweight.
  • SURMOUNT-3 followed an intensive lifestyle-intervention lead-in.
  • SURMOUNT-4 used a randomized-withdrawal design to study continued treatment and maintenance.
  • SURMOUNT-OSA studied adults with moderate-to-severe obstructive sleep apnea and obesity.
  • SURMOUNT-5 directly compared tirzepatide with semaglutide in a defined adult population.
  • SURMOUNT-MMO is an ongoing outcomes study beyond the current product indications.

These trials belong to one sponsor program but should not be pooled into a single unspecific result. Population, design, comparator, duration, endpoint, estimand, analysis, and regulatory use remain trial-level fields.

Regulatory and commercial interpretation

Section titled “Regulatory and commercial interpretation”

Mechanism activity is not itself a regulatory status. FDA approves named products for defined uses; it does not give every present or future GIP/GLP-1 agonist the Zepbound label.

Record Correct interpretation
Tirzepatide activates GIP and GLP-1 receptors Mechanism and ingredient fact
Zepbound is FDA-approved Product-, indication-, population-, application-, and date-specific status
Mounjaro contains tirzepatide Shared-ingredient relationship, not an obesity-label transfer
Retatrutide engages three receptor systems Investigational mechanism record, not market authorization
A company develops another dual agonist Pipeline relationship until a regulator grants a product-specific authorization

Mechanism grouping also does not establish launch, coverage, reimbursement, price, supply, local inventory, or commercial rights in a particular jurisdiction.

Safety and label boundaries

Section titled “Safety and label boundaries”

Safety information belongs to the named product label and studied population. The current Zepbound label contains a boxed warning, contraindications, warnings, precautions, adverse reactions, interactions, and population-specific information. A mechanism page cannot replace that label.

The label also states that coadministration of Zepbound with another tirzepatide-containing product or a GLP-1 receptor agonist is not recommended. That is a product-label limitation, not a basis for individualized prescribing guidance on this site.

What not to infer

Section titled “What not to infer”
  • GIP/GLP-1 receptor agonism does not mean that a product contains two active ingredients.
  • Tirzepatide is not synonymous with Zepbound or Mounjaro.
  • Shared receptor activity does not make products interchangeable.
  • More receptor targets do not automatically mean greater efficacy or lower risk.
  • Trial results from one population, comparator, dose, or duration do not transfer to another.
  • A development program or positive trial result does not establish regulatory approval.
  • FDA approval of Zepbound does not approve every GIP/GLP-1 agonist.
  • Mechanism and approval do not establish coverage, affordability, availability, or individual suitability.
  • This mechanism record is not treatment, dosing, switching, or prescribing guidance.
Section titled “Related records”